Friday, 29 October 2021
  
Login

Australia's most trusted
source of pharma news

Friday, 29 October 2021
News

Three ticks for MSD blockbuster

Posted 14 October 2021 AM

MSD's blockbuster Keytruda has had another huge run with the TGA revealing it approved three new indications for the drug last month.

Two of the three new indications were registered via the provisional approval pathway, enabling earlier access to the checkpoint inhibitor for patients with Tumour Mutational Burden-High (TMB-H) cancer and the second most common form of skin cancer.

To see the whole article, please login

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read. If you don't have a password, just enter your email address and then click Login.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 
 
 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.